• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Affinium Pharmaceuticals

edit

Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway.

Recent Milestones

edit

• 
  Affinium Pharmaceuticals received $15M in Venture Round funding. (8/29/11)
  Posted 8/29/11 at 7:25pm via afnm.com
• 
  Affinium Pharmaceuticals added Owen Roberts as CFO.
  Posted 8/29/11 at 7:25pm
• 
  Affinium Pharmaceuticals added Barry Hafkin as Chief Medical Officer.
  Posted 8/29/11 at 7:25pm
• 
  Affinium Pharmaceuticals added Ed Mascioli as Chief Executive Officer.
  Posted 3/27/13 at 8:27pm

Videos

Screenshots

edit

Sources

1. Affinium Pharmaceuticals Announces the Closing of $15 Million Financing (afnm.com) [edit]